IL1B and inflammatory bowel disease: When LYCO was given 3 days before IBD, it produced a significant (p < 0.01, 0.001, n = 6) reduction in the IL-1β levels from 301.30 ± 46.11 in the untreated group (IBD, no LYCO) to 76.90 ± 22.43 ng/mg of protein and from 140.78 ± 34.86 to 24.04 ± 3.34 ng/mg of protein, on days 2 and 4 of IBD, respectively.